Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTX 001 - Resolution Therapeutics

Next Previous
X
Search
Drug Profile

RTX 001 - Resolution Therapeutics

Alternative Names: RTX-001 - Resolution Therapeutics

Latest Information Update: 09 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Resolution Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Cell therapies; Gene therapies
  • Mechanism of Action Macrophage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Liver cirrhosis

Most Recent Events

  • 03 Oct 2024 Resolution Therapeutics plans the phase I/II EMERALD trial for Liver cirrhosis in United Kingdom and Spain (IV) in fourth quarter of 2024
  • 27 Jun 2024 UK Medicines and Healthcare products Regulatory Agency (MHRA) approves clinical trial application for RTX 001, to initiate the phase I/II EMERALD trial in Liver cirrhosis
  • 20 Jun 2024 Adverse events data from a phase I/II trial in Liver cirrhosis presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top